Brain Tumors Research

City of Hope is a hub of innovation and progress when it comes to treating brain tumors. Our research and clinical teams work together to advance therapies that more effectively — and directly — target brain tumors. A groundbreaking case study conducted at City of Hope, and published in the New England Journal of Medicine, found that using CAR T cell therapy, a type of immunotherapy, can be effective in the treatment of glioblastoma. And we are researching immunotherapy as a way of disabling cancer cells and finding unique ways to allow cancer drugs to cross the blood-brain barrier.

We are world leaders in the field of neural stem cell therapy, a groundbreaking method of delivering chemotherapy drugs directly to tumor sites within the brain — and were the first in the world to apply this exciting breakthrough therapy to brain cancer.

Brain Tumor Clinical Trials

The key to finding better treatments for aggressive diseases is the consta


nt collaboration between researchers, clinicians and oncologists — who move therapies swiftly from our on-campus research labs to patients. The quality and frequency of this interaction allows us to get potentially life-extending therapies to our patients quickly.

For more information about the brain tumor studies listed below, including eligibility criteria, please call 844-333-HOPE (4673). For a summary of these studies, visit City of Hope's clinical trials website.

Newly Diagnosed Gliomas

NCT04471844: We are recruiting patients to participate in this Phase 3 study, a multicenter study to test the effectiveness and safety of Optune given concomitantly with radiation therapy and temozolomide in newly diagnosed glioblastoma patients.

Principal Investigator: Jana Portnow, M.D.

Clinical Trials Icon

Patient Enrollment Qualifications

  • Age 18 years or older
  • Patients newly diagnosed with glioblastoma

Learn more about this promising study

Recurrent High-Grade Gliomas

NCT05218408: We are recruiting patients to participate in a trial to assess the safety and efficacy of CYNK-001 in combination with recombinant human interleukin-2 in adults with recurrent resection-eligible IDH1 wild-type glioblastoma.

Principal Investigator: Jana Portnow, M.D.

Clinical Trials Icon

Patient Enrollment Qualifications

  • Age 18 years or older
  • Glioblastoma patients at first or second recurrence

Learn more about this promising study

_______________________

NCT05139056: Patients with recurrent high-grade gliomas will soon have the opportunity to participate in a study to assess the safety and effectiveness of multiple doses of neural stem cells in combination with an oncolytic virus. 

Principal Investigator: Jana Portnow, M.D.

Clinical Trials Icon

Patient Enrollment Qualifications

  • Age 18 years or older
  • Diagnosed with recurrent high-grade glioma

Learn more about this promising study

_______________________

NCT05139043: We are recruiting patients to study whether low-dose dexamethasone works as well as standard-dose dexamethasone to reduce brain swelling after brain surgery in patients with primary brain tumors or cancer that has spread from other places in the body to the brain (metastatic).

Principal Investigator: Jana Portnow, M.D.

Clinical Trials Icon

Patient Enrollment Qualifications

  • Age 18 years or older
  • Patients with primary or metastatic brain tumors who need surgery to remove the tumor

Learn more about this promising study

_______________________

NCT04214392: We're recruiting for a study on the possible benefits and optimal doses of CAR T cells with a chlorotoxin tumor-targeting domain to treat MMP2+ recurrent high-grade gliomas.

Principal Investigator: Behnam Badie, M.D.

Clinical Trials Icon

Patient Enrollment Qualifications

  • Age 18 years or older
  • Diagnosed with recurrent high-grade glioma

Learn more about this promising study

_______________________

NCT03389230: If you've been diagnosed with recurrent high-grade gliomas, you may be eligible to participate in a study using memory-enriched T cells — specifically, HER2 (EQ) BBᶳ/CD19 t+ T cells aimed at killing glioma tumor cells.

Principal Investigator: Behnam Badie, M.D.

Clinical Trials Icon

Patient Enrollment Qualifications

  • Age 18 years or older
  • Diagnosed with recurrent high-grade glioma

Learn more about this promising study

_______________________

NCT04003649: We're recruiting patients for a study that combines two types of immunotherapy using CAR T cells together with nivolumab and/or ipilimumab.

Principal Investigator: Behnam Badie, M.D.

Clinical Trials Icon

Patient Enrollment Qualifications

  • Age 18 years or older
  • Diagnosed with recurrent high-grade glioma

Learn more about this promising study

_______________________

NCT04661384: Patients with leptomeningeal disease may be eligible to participate in a study of CAR T cell therapy to assess the benefits of treatment using brain tumor-specific immune cells.

Principal Investigator: Lisa Feldman, M.D., Ph.D.

Clinical Trials Icon

Patient Enrollment Qualifications

  • Age 18 years or older
  • Diagnosed with leptomeningeal metastases from glioblastoma, ependymoma or medulloblastoma

Learn more about this promising study

_______________________

NCT04510051: Children or young adults with recurrent malignant primary brain tumors can participate in a study to assess the safety and best dose of CAR T cell therapy.

Principal Investigator: Leo Wang, M.D, Ph.D.

Clinical Trials Icon

Patient Enrollment Qualifications

  • Age 4 to 25 years old
  • Recurrent malignant primary brain tumors

Learn more about this promising study

_______________________

NCT05267106: This is a multicenter study to evaluate the efficacy and safety of pemigatinib in participants with previously treated glioblastoma or other primary central nervous system tumors harboring activating FGFR1-3 alterations (FIGHT-209).

Principal Investigator: Jana Portnow, M.D.

Clinical Trials Icon

Patient Enrollment Qualifications

  • Age 18 years or older
  • Diagnosed with recurrent glioblastoma or other primary CNS tumors that have an FGFR 1-3 alteration

Learn more about this promising study

Brain Metastases

NCT03696030: We're recruiting for a study to evaluate the possible benefits of CAR T cells in patients with recurrent HER2+ brain and/or leptomeningeal metastases.

Principal Investigator: Jana Portnow, M.D.

Clinical Trials Icon

Patient Enrollment Qualifications

  • Age 18 to 75 years old
  • Diagnosed with HER2+ brain and/or leptomeningeal metastases
Learn more about this promising study